Psilocybin Therapy for Psychological Distress in Palliative Patients
Phase 2 study registered on ClinicalTrials.gov. Condition: COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis). Interventions listed: Psilocybin therapy. Lead sponsor: University Medical Center Groningen. Sites in: Czechia, Denmark, Netherlands, Portugal (4 sites).
Trial listings come from public registries. Taking part is up to the study team, who will check your eligibility. Recruitment status can change at any time, so check the registry record first.
- Type
- Recruiting trial
- Location
- Prague, Czechia
- Countries
- Czechia, Denmark, Netherlands, Portugal
- Status
- Recruiting (ClinicalTrials.gov)
- Registry
- ClinicalTrials.gov · NCT06782724
- Sponsor
- University Medical Center Groningen
- Condition
- COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis)
- Website
- https://clinicaltrials.gov/study/NCT06782724
- Source
- https://clinicaltrials.gov/study/NCT06782724
- Last verified
- 21 October 2026
About this directory. Psyche Insights lists organisations for information only. A listing is not an endorsement, a recommendation or medical advice, and we do not take referral fees. We list only lawful, regulated services, registered clinical trials and professional training. We do not list retreats or anyone offering psychedelics outside the law. Psilocybin, MDMA, LSD and DMT are controlled drugs in the UK. Eligibility, availability and legal status differ by country and change often. Always check details with the provider or trial team, and talk to your GP or specialist before making any treatment decision. Paid placements are labelled “Featured · Paid placement” and never change our editorial descriptions. See our terms.
Corrections and removal. Spotted an error, or represent a listed organisation and want a listing corrected, updated or removed? Email [email protected] with the page link and the change needed. We aim to reply within 5 working days.
Follow access news each week
New trials, approvals and access routes, UK and Europe first.
Subscribe free →